Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy (bronchoprotection) and safety
of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the
Respimat® inhaler, in patients with intermittent asthma.